DANONE (BSN.DE) Fundamental Analysis & Valuation
FRA:BSN • FR0000120644
Current stock price
69 EUR
-0.32 (-0.46%)
Last:
This BSN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BSN.DE Profitability Analysis
1.1 Basic Checks
- In the past year BSN was profitable.
- In the past year BSN had a positive cash flow from operations.
- Each year in the past 5 years BSN has been profitable.
- Each year in the past 5 years BSN had a positive operating cash flow.
1.2 Ratios
- BSN has a Return On Assets of 4.03%. This is comparable to the rest of the industry: BSN outperforms 59.02% of its industry peers.
- Looking at the Return On Equity, with a value of 10.73%, BSN is in the better half of the industry, outperforming 60.66% of the companies in the same industry.
- BSN has a better Return On Invested Capital (7.75%) than 65.57% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 7.13%.
- The last Return On Invested Capital (7.75%) for BSN is above the 3 year average (7.51%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.03% | ||
| ROE | 10.73% | ||
| ROIC | 7.75% |
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
1.3 Margins
- With a decent Profit Margin value of 6.66%, BSN is doing good in the industry, outperforming 63.93% of the companies in the same industry.
- In the last couple of years the Profit Margin of BSN has declined.
- BSN has a better Operating Margin (13.43%) than 86.89% of its industry peers.
- In the last couple of years the Operating Margin of BSN has remained more or less at the same level.
- Looking at the Gross Margin, with a value of 50.62%, BSN belongs to the top of the industry, outperforming 85.25% of the companies in the same industry.
- In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.43% | ||
| PM (TTM) | 6.66% | ||
| GM | 50.62% |
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
2. BSN.DE Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BSN is creating some value.
- The number of shares outstanding for BSN has been reduced compared to 1 year ago.
- The number of shares outstanding for BSN has been reduced compared to 5 years ago.
- The debt/assets ratio for BSN is higher compared to a year ago.
2.2 Solvency
- BSN has an Altman-Z score of 2.38. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 2.38, BSN is in line with its industry, outperforming 57.38% of the companies in the same industry.
- The Debt to FCF ratio of BSN is 5.29, which is a neutral value as it means it would take BSN, 5.29 years of fcf income to pay off all of its debts.
- BSN has a better Debt to FCF ratio (5.29) than 67.21% of its industry peers.
- BSN has a Debt/Equity ratio of 0.73. This is a neutral value indicating BSN is somewhat dependend on debt financing.
- BSN has a worse Debt to Equity ratio (0.73) than 63.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 5.29 | ||
| Altman-Z | 2.38 |
ROIC/WACC1.22
WACC6.36%
2.3 Liquidity
- A Current Ratio of 0.90 indicates that BSN may have some problems paying its short term obligations.
- BSN's Current ratio of 0.90 is on the low side compared to the rest of the industry. BSN is outperformed by 80.33% of its industry peers.
- A Quick Ratio of 0.75 indicates that BSN may have some problems paying its short term obligations.
- The Quick ratio of BSN (0.75) is worse than 60.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.75 |
3. BSN.DE Growth Analysis
3.1 Past
- The Earnings Per Share has been growing slightly by 4.68% over the past year.
- Measured over the past 5 years, BSN shows a small growth in Earnings Per Share. The EPS has been growing by 2.61% on average per year.
- Looking at the last year, BSN shows a decrease in Revenue. The Revenue has decreased by -0.34% in the last year.
- BSN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.93% yearly.
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
3.2 Future
- The Earnings Per Share is expected to grow by 7.81% on average over the next years.
- BSN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.25% yearly.
EPS Next Y7.51%
EPS Next 2Y7.63%
EPS Next 3Y7.85%
EPS Next 5Y7.81%
Revenue Next Year2.57%
Revenue Next 2Y3.27%
Revenue Next 3Y3.55%
Revenue Next 5Y4.25%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. BSN.DE Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 18.16, which indicates a rather expensive current valuation of BSN.
- BSN's Price/Earnings is on the same level as the industry average.
- BSN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.91.
- Based on the Price/Forward Earnings ratio of 16.89, the valuation of BSN can be described as correct.
- The rest of the industry has a similar Price/Forward Earnings ratio as BSN.
- BSN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.69, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.16 | ||
| Fwd PE | 16.89 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as BSN.
- Based on the Price/Free Cash Flow ratio, BSN is valued a bit cheaper than the industry average as 67.21% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.25 | ||
| EV/EBITDA | 9.5 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.42
PEG (5Y)6.95
EPS Next 2Y7.63%
EPS Next 3Y7.85%
5. BSN.DE Dividend Analysis
5.1 Amount
- BSN has a Yearly Dividend Yield of 3.35%.
- Compared to an average industry Dividend Yield of 2.95, BSN pays a bit more dividend than its industry peers.
- Compared to an average S&P500 Dividend Yield of 1.89, BSN pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.35% |
5.2 History
- The dividend of BSN has a limited annual growth rate of 0.46%.
Dividend Growth(5Y)0.46%
Div Incr Years4
Div Non Decr Years5
5.3 Sustainability
- BSN pays out 75.94% of its income as dividend. This is not a sustainable payout ratio.
- The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP75.94%
EPS Next 2Y7.63%
EPS Next 3Y7.85%
BSN.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:BSN (4/8/2026, 7:00:00 PM)
69
-0.32 (-0.46%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-20 2026-02-20/bmo
Earnings (Next)04-22 2026-04-22
Inst Owners53.9%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap47.02B
Revenue(TTM)27.28B
Net Income(TTM)1.82B
Analysts75.76
Price Target80.77 (17.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.35% |
Yearly Dividend2.15
Dividend Growth(5Y)0.46%
DP75.94%
Div Incr Years4
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.1%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.16 | ||
| Fwd PE | 16.89 | ||
| P/S | 1.72 | ||
| P/FCF | 17.25 | ||
| P/OCF | 12.44 | ||
| P/B | 2.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.5 |
EPS(TTM)3.8
EY5.51%
EPS(NY)4.09
Fwd EY5.92%
FCF(TTM)4
FCFY5.8%
OCF(TTM)5.55
OCFY8.04%
SpS40.04
BVpS24.83
TBVpS-9.13
PEG (NY)2.42
PEG (5Y)6.95
Graham Number46.07
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.03% | ||
| ROE | 10.73% | ||
| ROCE | 12.04% | ||
| ROIC | 7.75% | ||
| ROICexc | 9.68% | ||
| ROICexgc | 76.66% | ||
| OM | 13.43% | ||
| PM (TTM) | 6.66% | ||
| GM | 50.62% | ||
| FCFM | 9.99% |
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
ROICexc(3y)9.24%
ROICexc(5y)8.74%
ROICexgc(3y)70.2%
ROICexgc(5y)59.95%
ROCE(3y)11.59%
ROCE(5y)10.94%
ROICexgc growth 3Y20.15%
ROICexgc growth 5Y16.9%
ROICexc growth 3Y6.6%
ROICexc growth 5Y4.3%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 5.29 | ||
| Debt/EBITDA | 2.46 | ||
| Cap/Depr | 77.86% | ||
| Cap/Sales | 3.87% | ||
| Interest Coverage | 21.06 | ||
| Cash Conversion | 75.3% | ||
| Profit Quality | 150.06% | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | 2.38 |
F-Score7
WACC6.36%
ROIC/WACC1.22
Cap/Depr(3y)69.82%
Cap/Depr(5y)67.75%
Cap/Sales(3y)3.44%
Cap/Sales(5y)3.55%
Profit Quality(3y)197.16%
Profit Quality(5y)188.14%
High Growth Momentum
Growth
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
EPS Next Y7.51%
EPS Next 2Y7.63%
EPS Next 3Y7.85%
EPS Next 5Y7.81%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
Revenue Next Year2.57%
Revenue Next 2Y3.27%
Revenue Next 3Y3.55%
Revenue Next 5Y4.25%
EBIT growth 1Y3.01%
EBIT growth 3Y2.73%
EBIT growth 5Y1.96%
EBIT Next Year36.75%
EBIT Next 3Y14.85%
EBIT Next 5Y11.54%
FCF growth 1Y-6.26%
FCF growth 3Y9.25%
FCF growth 5Y6.33%
OCF growth 1Y-1.31%
OCF growth 3Y8.46%
OCF growth 5Y4.96%
DANONE / BSN.DE Fundamental Analysis FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status for BSN stock?
ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for DANONE?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What is the financial health of DANONE (BSN.DE) stock?
The financial health rating of DANONE (BSN.DE) is 3 / 10.
Can you provide the dividend sustainability for BSN stock?
The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 75.94%.